Horiba John Yvon has reported progress in its ongoing collaborative efforts to develop a Surface Plasmon Resonance imaging (SPRi)-based mass spectrometry (MS) device.

In association with the CLIPP proteomic platform, the company has contracted a CIFRE research fellow to assist in the clinical validation of its new SPRi-MS system the SuPRA-MS.

Among the benefits it expects to see as a result of this move are advances in the nano/micro-technologies as adapted for biochips, automation of on-chip MS analyses and development of bio-statistical tools specifically for the platform.

According to Horiba John Yvon, these advances are important due to the previous difficulties associated with creating instruments which can combine multiplexed detection and biological analytes identification functionality.

It says the development of such a device can assist in early disease detection and research into personalised therapies.

Other benefits of the Supra-MS platform highlighted by the manufacturer include its label-free detection of biomolecular interactions.